LENZ Therapeutics Q3 Earnings Call Highlights

LENZ Therapeutics NASDAQ: LENZ reported third-quarter 2026 product revenue of $2.6 million, up 50% sequentially, as prescriptions for its presbyopia eye drop VIZZ increased following the expansion of national advertising and the launch of a telehealth channel.

MarketBeat • 10 hours ago

LENZ Therapeutics, Inc. (LENZ) Q3 2026 Earnings Call Transcript

LENZ Therapeutics, Inc. ( LENZ ) Q3 2026 Earnings Call October 29, 2026 8:30 AM EDT Company Participants Daniel Chevallard - CFO, Principal Financial & Accounting Officer Evert Schimmelpennink - President, CEO, Secretary & Director Shawn Olsson - Chief Commercial Officer Conference Call Participants Stacy Ku - TD Cowen, Research Division Alyssa Larios - Leerink Partners LLC, Research Division Yigal Nochomovitz - Citigroup Inc. Exchange Research Lachlan Hanbury-Brown - William Blair & Company L.L.C., Research Division Jason Gerberry - BofA Securities, Research Division Matthew Caufield - H.C.

Seeking Alpha • 8 hours ago

LENZ Therapeutics Reports Third Quarter 2026 Financial Results, Announces Strategic Consumer Marketing Focused Reorganization and CEO Succession

Q3 2026 VIZZ® product sales increased 50% over prior quarter, with strong momentum continuing into Q4 as consumer awareness broadens and telehealth adoption increases

GlobeNewsWire • Oct 28, 2026

LENZ Therapeutics, Inc. (LENZ) Reports Q3 Loss, Misses Revenue Estimates

LENZ Therapeutics, Inc. (LENZ) came out with a quarterly loss of $0.99 per share versus the Zacks Consensus Estimate of a loss of $0.97. This compares to a loss of $0.59 per share a year ago.

Zacks Investment Research • Oct 28, 2026

LENZ Therapeutics to Report Third Quarter 2026 Financial Results on October 29, 2026

SAN DIEGO, Oct. 22, 2026 (GLOBE NEWSWIRE) -- LENZ Therapeutics, Inc. (Nasdaq: LENZ or “LENZ” or the “Company”), a pharmaceutical company focused on the commercialization of VIZZ® (aceclidine ophthalmologic solution) 1.44%, the first and only FDA-approved aceclidine-based eye drop for the treatment of presbyopia in adults, today announced that it will host a webcast on Thursday, October 29, 2026, at 8:30 a.m. EDT to report its third quarter 2026 financial results.

GlobeNewsWire • Oct 22, 2026

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of LENZ Therapeutics, Inc. - LENZ

NEW YORK, Oct. 06, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of LENZ Therapeutics, Inc. (“Lenz” or the “Company”) (NASDAQ: LENZ). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.

GlobeNewsWire • Oct 6, 2026

These beaten-down stocks could bounce back in January, if history is any guide

Tax-loss selling is likely to lead these 20 stocks to become artificially depressed in the fourth quarter — and therefore good bets to bounce back in the new year

Market Watch • Sep 21, 2026

LENZ Therapeutics: Still Speculative But Priced For Disasters

LENZ Therapeutics is rated a 'Strong Buy' with a fair value estimate of $21.3, reflecting ~266% upside from current levels. I model peak US Vizz sales at $375M, using a 5-pack annualized purchase rate and 30% market share, with conservative international assumptions. LENZ's speculative nature persists due to single-product risk, high SG&A, uninsured status, and rising competition; position sizing remains limited.

Seeking Alpha • Sep 4, 2026

LENZ Therapeutics, Inc. (LENZ) Q2 2026 Earnings Call Transcript

LENZ Therapeutics, Inc. (LENZ) Q2 2026 Earnings Call Transcript

Seeking Alpha • Aug 12, 2026

LENZ Therapeutics Q2 Earnings Call Highlights

LENZ Therapeutics NASDAQ: LENZ reported second-quarter revenue of $5.5 million as it continued the commercial launch of VIZZ, citing modest quarterly growth and a pickup in prescription activity following the July rollout of national television advertising and a telehealth access option.

MarketBeat • Aug 11, 2026